AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 6, 2026.

via HealthDay

MONDAY, April 6, 2026 -- Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone in adults with overweight or obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

Joseph F. Merola, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues evaluated the efficacy and safety of IXE+TZP versus IXE alone in adults with active PsA and overweight with one or more weight-related comorbidity or obesity. The analysis included 138 individuals on IXE+TZP and 133 on IXE as part of the TOGETHER-PsA phase 3b study.

The researchers found that 71.6 percent of participants had psoriasis, and 18.8 percent had failed at least two classes of advanced therapies. Just under one-third of participants (31.7 percent) achieved the primary outcome of simultaneous achievement of American College of Rheumatology 50 percent (ACR50) improvement and ≥10 percent weight reduction at week 36 with IXE+TZP compared with 0.8 percent for IXE alone. There was a meaningful difference in ACR50 in IXE+TZP (33.5 percent) versus IXE alone (20.4 percent), with a significant improvement seen as early as week 4. IXE+TZP led to a significant difference in absolute Psoriasis Area and Severity Index change from baseline. Additionally, there were significant improvements in measures of physical function, fatigue, and mental and physical health. No new safety signals were seen. Treatment discontinuations due to adverse events were similar between treatment groups.

"Significant comprehensive improvement in disease activity was demonstrated with IXE+TZP compared to IXE alone in active PsA, with no new safety concerns," the authors write.

The study was sponsored by Eli Lilly, the manufacturer of ixekizumab and tirzepatide.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-07 01:53

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords